Travere Therapeutics today announced that the Company will present seven abstracts at the upcoming ERA Congress in Vienna, Austria, in June.

STOCKHOLM, SE / ACCESS Newswire / May 22, 2025 / Vicore Pharma Holding (STO:VICO) - Stockholm, May 22, 2025 - Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, ...

ACE2 lowers angiotensin II levels by converting it to ... but we couldn't do that because its activity was killed by all ACE inhibitors except for lisinopril." Ultimately, Daniell would like ...

and to evaluate its potential for improving angiotensin II (Ang II)-mediated adverse effects on vascular smooth muscle cells (VSMCs). A novel ACE-inhibitory peptide with the highest activity from the ...

Table 2. Linear regression analysis for the factors that may influence plasma renin activity (PRA), aldosterone and angiotensin II concentrations. Table 4. Effect of bisoprolol on plasma renin ...

vasodilation reduced platelet aggregation and enhanced insulin activity. Angiotensin II also acts on the brain where it can bind to the hypothalamus to stimulate thirst to increase water intake.

Specifically, we discuss the uncertain effects of RAAS blockers on ACE2 levels and activity ... primarily type II pneumocytes, after binding to its functional receptor, angiotensin-converting ...

Angiotensin II (AngII) is a key neuropeptide that acting within the brain ... Although AngII effects involve changes in paraventricular nucleus neuronal activity, the precise underlying mechanisms, ...

Compared with other antihypertensive drugs, long-term use (≥ 12 months) of ACEis or ARBs showed additional benefits of preserving residual kidney function in CAPD patients. There was no significant ...

Ang II did not activate PP2C enzymatic activity in addition to increasing PP2Cα expression ... disease states characterized by chronic activation of the renin-angiotensin system and muscle wasting.